BR0312007A - Controle de taxa de administração transcutânea usando composições farmacêuticas amorfas - Google Patents
Controle de taxa de administração transcutânea usando composições farmacêuticas amorfasInfo
- Publication number
- BR0312007A BR0312007A BR0312007-4A BR0312007A BR0312007A BR 0312007 A BR0312007 A BR 0312007A BR 0312007 A BR0312007 A BR 0312007A BR 0312007 A BR0312007 A BR 0312007A
- Authority
- BR
- Brazil
- Prior art keywords
- physiologically active
- transcutaneous administration
- pharmaceutical compositions
- active agent
- rate control
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39108102P | 2002-06-25 | 2002-06-25 | |
PCT/AU2003/000787 WO2004000263A1 (en) | 2002-06-25 | 2003-06-24 | Transdermal delivery rate control using amorphous pharmaceutical compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
BR0312007A true BR0312007A (pt) | 2005-04-12 |
BRPI0312007B1 BRPI0312007B1 (pt) | 2015-04-14 |
Family
ID=30000668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0312007-4A BRPI0312007B1 (pt) | 2002-06-25 | 2003-06-24 | Composição farmacêutica para administração transcutânea de testosterona ou fentanil e uso da dita composição |
Country Status (12)
Country | Link |
---|---|
US (4) | US8357393B2 (pt) |
EP (2) | EP1534235B1 (pt) |
JP (2) | JP5160018B2 (pt) |
KR (2) | KR20050045946A (pt) |
AU (1) | AU2003240301B2 (pt) |
BR (1) | BRPI0312007B1 (pt) |
CA (1) | CA2489865C (pt) |
EA (1) | EA009024B1 (pt) |
ES (1) | ES2589077T3 (pt) |
HK (1) | HK1077192A1 (pt) |
NZ (1) | NZ537360A (pt) |
WO (1) | WO2004000263A1 (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
KR20050045946A (ko) | 2002-06-25 | 2005-05-17 | 애크럭스 디디에스 피티와이 리미티드 | 비정질 약학적 조성물을 이용한 경피전달속도의 제어 |
US20050181032A1 (en) * | 2002-06-25 | 2005-08-18 | Acrux Dds Pty Ltd. | Metastable pharmaceutical compositions |
US20050186141A1 (en) * | 2002-06-25 | 2005-08-25 | Acrux Dds Pty Ltd. | Transdermal aerosol compositions |
US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
EP1426049B1 (en) * | 2002-12-02 | 2005-05-18 | Schwarz Pharma Ag | Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease |
DE10261696A1 (de) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
GB0306859D0 (en) * | 2003-03-25 | 2003-04-30 | Arachnova Therapeutics Ltd | Topical formulation and use of buspirone |
GB0319874D0 (en) * | 2003-08-22 | 2003-09-24 | Glaxo Group Ltd | Novel formulation |
US20060263421A1 (en) | 2005-05-18 | 2006-11-23 | Abeille Pharmaceuticals Inc | Transdermal Method and Patch for Nausea |
MX2007015255A (es) * | 2005-06-03 | 2008-02-22 | Acrux Dds Pty Ltd | Metodo y composicion para administracion transdermica de un farmaco. |
NZ563946A (en) * | 2005-06-03 | 2012-02-24 | Acrux Dds Pty Ltd | Testosterone containing non-occlusive transdermal drug delivery composition for application to the arm pit / axilla |
US20070065494A1 (en) * | 2005-08-03 | 2007-03-22 | Watson Laboratories, Inc. | Formulations and Methods for Enhancing the Transdermal Penetration of a Drug |
CN103787927B (zh) | 2006-10-12 | 2017-03-01 | Bhi有限合资公司 | 递送3‑氨基‑1‑丙磺酸的方法、化合物、组合物和载体 |
IN2009KN02397A (pt) | 2007-01-11 | 2015-08-07 | Acrux Dds Pty Ltd | |
AR068409A1 (es) * | 2007-09-14 | 2009-11-18 | Drugtech Corp | Composiciones farmaceuticas, transdermicas sin alcohol |
AR068408A1 (es) * | 2007-09-14 | 2009-11-18 | Drugtech Corp | Pulverizacion de hormonas transdermicas |
US20100279988A1 (en) * | 2007-11-02 | 2010-11-04 | Acrux Dds Pty Ltd. | Transdermal delivery system for hormones and steroids |
KR100929560B1 (ko) * | 2008-01-09 | 2009-12-03 | 에코 퍼시픽 엘티디 | 그라니세트론을 함유한 매트릭스 형태의 경피 흡수제 |
US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
KR101292768B1 (ko) * | 2010-04-23 | 2013-08-05 | 아이큐어 주식회사 | 경피 흡수 제제 |
US9017723B2 (en) | 2010-04-30 | 2015-04-28 | Teikoku Pharma Usa, Inc. | Propynylaminoindan transdermal compositions |
US20130267562A1 (en) * | 2010-12-02 | 2013-10-10 | Nexmed Holdings, Inc | Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate |
KR101526781B1 (ko) | 2011-02-15 | 2015-06-05 | 일라이 릴리 앤드 캄파니 | 펜타닐의 경피 용액을 사용하여 개에서 통증을 제어하는 방법 |
WO2012112355A1 (en) * | 2011-02-15 | 2012-08-23 | Eli Lilly And Company | Methods for controlling pain in equines using a transdermal solution of fentanyl |
WO2012129429A2 (en) | 2011-03-24 | 2012-09-27 | Teikoku Pharma Usa, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
WO2013070526A1 (en) | 2011-11-09 | 2013-05-16 | Teikoku Pharma Usa, Inc. | Methods for the treatment of skin neoplasms |
US9205061B2 (en) | 2012-11-02 | 2015-12-08 | Teikoku Pharma Usa, Inc. | Propynylaminoindan transdermal compositions |
WO2014152454A1 (en) * | 2013-03-15 | 2014-09-25 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing rivastigmine |
USD749225S1 (en) | 2013-11-26 | 2016-02-09 | Acrux Dds Pty Ltd | Topical spreading applicator |
USD750788S1 (en) | 2013-11-26 | 2016-03-01 | Acrux Dds Pty Ltd | Topical spreading applicator |
US8785426B1 (en) | 2013-12-13 | 2014-07-22 | Upsher-Smith Laboratories, Inc. | Testosterone gel compositions and related methods |
TW201705962A (zh) | 2015-03-23 | 2017-02-16 | 生物製藥X公司 | 皮膚用四環素醫藥組成物 |
JP2018177724A (ja) * | 2017-04-18 | 2018-11-15 | 花王株式会社 | 外用薬 |
WO2019140087A1 (en) * | 2018-01-10 | 2019-07-18 | Celista Pharmaceuticals Llc | Testosterone transdermal spray with film |
EP3817731A4 (en) * | 2018-07-05 | 2022-04-06 | Celista Pharmaceuticals Llc | TRANSDERMAL TESTOSTERONE AND ESTRADIOL SPRAY |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE555319A (pt) * | 1956-03-21 | 1900-01-01 | ||
GB1192003A (en) | 1966-05-25 | 1970-05-13 | Struthers Scientific Int Corp | Improvements in or relating to Hair Dressing Preparation |
GB1258394A (pt) | 1968-01-17 | 1971-12-30 | ||
GB1560401A (en) | 1976-01-28 | 1980-02-06 | Unilever Ltd | Skin treatment composition |
DE2920500A1 (de) | 1979-05-21 | 1980-11-27 | Boehringer Sohn Ingelheim | Pharmazeutische zubereitung in form eines polyacrylatfilmes |
US4506803A (en) * | 1982-08-09 | 1985-03-26 | Hoffmann-La Roche Inc. | Metered aerosol dispenser and method of using the dispenser |
DE3311700A1 (de) * | 1983-03-30 | 1984-10-04 | Bayer Ag | Antimykotische mittel mit hoher wirkstoff-freisetzung in form von loesung und spray |
US4912124A (en) * | 1984-02-23 | 1990-03-27 | Ortho Pharmaceutical Corporation | Antifungal dermatological solution |
US4824676A (en) | 1984-10-11 | 1989-04-25 | Schering Corporation | Physiological means of enhancing transdermal delivery of drugs |
US5008111A (en) | 1984-10-11 | 1991-04-16 | Schering Corporation | Physiological means of enhancing transdermal delivery of drugs |
US4820724A (en) * | 1986-03-31 | 1989-04-11 | University Of Southern California | Dual phase solvent carrier system |
US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5474783A (en) | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5082866A (en) * | 1988-06-01 | 1992-01-21 | Odontex, Inc. | Biodegradable absorption enhancers |
US5164406A (en) | 1988-06-02 | 1992-11-17 | Bristol-Myers Squibb Co. | Method for enhancing transdermal penetration and compositions useful therein |
US5788983A (en) | 1989-04-03 | 1998-08-04 | Rutgers, The State University Of New Jersey | Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes |
CA2020964A1 (en) | 1989-07-12 | 1991-01-13 | Emmett M. Partain, Iii | Pharmaceutical active derivative delivery systems |
US5091186A (en) | 1989-08-15 | 1992-02-25 | Cygnus Therapeutic Systems | Biphasic transdermal drug delivery device |
JPH0794378B2 (ja) | 1989-08-18 | 1995-10-11 | 久光製薬株式会社 | エアゾール剤 |
JPH0383924A (ja) | 1989-08-28 | 1991-04-09 | Kanebo Ltd | 経皮投与用組成物 |
IL95952A0 (en) * | 1989-10-19 | 1991-07-18 | Sterling Drug Inc | Aerosol composition for topical medicament |
JP3046346B2 (ja) | 1990-03-12 | 2000-05-29 | 昭和電工株式会社 | 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤 |
US5118494A (en) * | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
JP2974081B2 (ja) | 1990-07-26 | 1999-11-08 | 小池化学株式会社 | 人体用エアゾール組成物 |
EP0553298B1 (en) | 1990-10-18 | 1994-11-17 | Minnesota Mining And Manufacturing Company | Aerosol formulation comprising beclomethasone 17,21 dipropionate |
US5122383A (en) | 1991-05-17 | 1992-06-16 | Theratech, Inc. | Sorbitan esters as skin permeation enhancers |
ATE157864T1 (de) * | 1991-12-18 | 1997-09-15 | Warner Lambert Co | Verfahren für die herstellung einer festen dispersion |
EP0560014A1 (en) | 1992-03-12 | 1993-09-15 | Atrix Laboratories, Inc. | Biodegradable film dressing and method for its formation |
NZ253409A (en) | 1992-06-11 | 1996-09-25 | Theratech Inc | Drug delivery system; transdermal/transmucosal system using glycerine to moderate drug delivery |
CA2101496A1 (en) | 1992-07-31 | 1994-02-01 | Masao Kobayashi | Base for transdermal administration |
DE4230588C1 (de) | 1992-09-12 | 1993-10-07 | Lohmann Therapie Syst Lts | Dexpanthenol-haltiges Pflaster zur transdermalen Applikation von Steroidhormonen und Verfahren zu seiner Herstellung |
US5613958A (en) | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
DE4334553C2 (de) * | 1993-10-11 | 1998-05-20 | Synopharm Gmbh Pharmazeutische | Flüssiges pharmazeutisches System zur perkutanen Applikation |
DE4446600A1 (de) | 1994-12-24 | 1996-06-27 | Lohmann Therapie Syst Lts | Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen |
US6416760B2 (en) * | 1995-01-26 | 2002-07-09 | Societe L'oreal | Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin |
GB9504265D0 (en) * | 1995-03-03 | 1995-04-19 | Medeva Plc | Corticosteroid-containing pharmaceutical composition |
FR2732223B1 (fr) | 1995-03-30 | 1997-06-13 | Sanofi Sa | Composition pharmaceutique pour administration transdermique |
US5780050A (en) | 1995-07-20 | 1998-07-14 | Theratech, Inc. | Drug delivery compositions for improved stability of steroids |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US6916487B2 (en) * | 1996-02-19 | 2005-07-12 | Acrux Dds Pty Ltd | Transdermal delivery of antiemetics |
US6929801B2 (en) * | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
US6923983B2 (en) * | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
US6916486B2 (en) * | 1996-02-19 | 2005-07-12 | Acrux Dds Pty Ltd | Transdermal delivery of analgesics |
US6998138B2 (en) * | 1996-02-19 | 2006-02-14 | Acrux Dds Pty. Ltd. | Topical delivery of anti-alopecia agents |
US7094422B2 (en) * | 1996-02-19 | 2006-08-22 | Acrux Dds Pty Ltd. | Topical delivery of antifungal agents |
US6004969A (en) * | 1996-04-15 | 1999-12-21 | National Science Council | Transdermal delivery of buprenorphine preparations |
DE19616539A1 (de) * | 1996-04-25 | 1997-11-06 | Luitpold Pharma Gmbh | Acetylsalicylsäure enthaltende alkoholische Lösungen zur perkutanen Anwendung, deren Verwendung zur antithrombotischen Therapie sowie Arzneimittel |
US6638948B1 (en) | 1996-09-09 | 2003-10-28 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
AUPO379596A0 (en) * | 1996-11-22 | 1996-12-19 | Soltec Research Pty Ltd | Percutaneous delivery system |
DE19701949A1 (de) | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
IT1294748B1 (it) * | 1997-09-17 | 1999-04-12 | Permatec Tech Ag | Formulazione per un dispositivo transdermico |
US5968919A (en) | 1997-10-16 | 1999-10-19 | Macrochem Corporation | Hormone replacement therapy drug formulations for topical application to the skin |
US6319913B1 (en) | 1997-11-10 | 2001-11-20 | Cellegy Pharmaceuticals, Inc. | Penetration enhancing and irritation reducing systems |
EP0919550A1 (en) * | 1997-11-26 | 1999-06-02 | Ucb, S.A. | Pseudopolymorphic forms of 2-2-4-bis(4-fluorophenyl)methyl-1-piperazinyl-ethoxy acetic acid dihydrochloride |
NZ509489A (en) * | 1998-08-04 | 2002-10-25 | Jago Res A | Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil |
US5962505A (en) * | 1998-08-31 | 1999-10-05 | Bobrove; Arthur M. | Method for treating hot flashes in humans |
DE19843027A1 (de) * | 1998-09-19 | 2000-03-23 | Labtec Gmbh | Neohesperidin DC als Kristallisationsinhibitor |
US6663874B2 (en) * | 1998-11-02 | 2003-12-16 | Victor Stevens | Composition to alleviate pain and topical method of applying same |
PT1150661E (pt) * | 1999-02-05 | 2004-02-27 | Cipla Ltd | Produto para pulverizacao para aplicacao topica |
DE19906152B4 (de) | 1999-02-10 | 2005-02-10 | Jenapharm Gmbh & Co. Kg | Wirkstoffhaltige Laminate für Transdermalsysteme |
US6399093B1 (en) * | 1999-05-19 | 2002-06-04 | Advanced Medical Instruments | Method and composition to treat musculoskeletal disorders |
JP2001270826A (ja) | 1999-09-28 | 2001-10-02 | Shoei:Kk | 皮膚疾患治療・予防用外用剤 |
EP1231877A4 (en) * | 1999-11-04 | 2009-03-18 | Xel Herbaceuticals | TRANSDERMALE ADMINISTRATION OF HUPERZIN |
AU4515001A (en) * | 1999-12-02 | 2001-06-18 | Regents Of The University Of Michigan, The | Compositions and methods for locally treating inflammatory diseases |
US6432415B1 (en) * | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
JP2004159666A (ja) * | 1999-12-21 | 2004-06-10 | Ya Man Ltd | レーザ脱毛器 |
IN191512B (pt) * | 2000-01-21 | 2003-12-06 | Panacea Biotech | |
US6562790B2 (en) | 2000-02-05 | 2003-05-13 | Chein Edmund Y M | Hormone therapy methods and hormone products for abating coronary artery blockage |
US6387383B1 (en) * | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
IN191090B (pt) * | 2000-08-29 | 2003-09-20 | Ranbanx Lab Ltd | |
WO2002017927A1 (en) | 2000-08-30 | 2002-03-07 | Unimed Pharmaceuticals, Inc. | Method for treating erectile dysfunction and increasing libido in men |
US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
IL154693A0 (en) | 2000-08-30 | 2003-09-17 | Unimed Pharmaceuticals Inc | Method of increasing testosterone and related steroid concentrations in women |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US6682757B1 (en) | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
GB0029634D0 (en) * | 2000-12-05 | 2001-01-17 | Norway Medical Group Int As | Use |
WO2002055020A2 (en) | 2000-12-11 | 2002-07-18 | Testocreme Llc | Topical testosterone formulations and associated methods |
AU2003206183A1 (en) | 2002-01-26 | 2003-09-02 | Micro Science Tech Co., Ltd | Composition containing moutan root bark extract as active ingredient |
US20030199584A1 (en) | 2002-04-11 | 2003-10-23 | Ahluwalia Gurpreet S. | Reduction of hair growth |
US20050186141A1 (en) * | 2002-06-25 | 2005-08-25 | Acrux Dds Pty Ltd. | Transdermal aerosol compositions |
US20050181032A1 (en) * | 2002-06-25 | 2005-08-18 | Acrux Dds Pty Ltd. | Metastable pharmaceutical compositions |
KR20050045946A (ko) * | 2002-06-25 | 2005-05-17 | 애크럭스 디디에스 피티와이 리미티드 | 비정질 약학적 조성물을 이용한 경피전달속도의 제어 |
AUPS317102A0 (en) * | 2002-06-25 | 2002-07-18 | Drug Delivery Solutions Pty Ltd | Transdermal aerosol compositions |
US8206696B2 (en) | 2002-12-30 | 2012-06-26 | Aplicare, Inc. | Antimicrobial skin preparation |
GB0302662D0 (en) | 2003-02-05 | 2003-03-12 | Strakan Ltd | Transdermal granisetron |
FR2851470B1 (fr) | 2003-02-20 | 2007-11-16 | Besins Int Belgique | Composition pharmaceutique pour administration transdermique ou transmuqueuse |
CA2433101A1 (en) * | 2003-06-23 | 2004-12-23 | Igor Gonda | Method of treatment of a female suffering from androgen insufficiency |
US20050025833A1 (en) | 2003-07-16 | 2005-02-03 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050042268A1 (en) | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050020552A1 (en) * | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
BRPI0414551B8 (pt) | 2003-10-10 | 2021-05-25 | Antares Pharma Ipl Ag | formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo |
AU2004290464A1 (en) * | 2003-11-19 | 2005-06-02 | Acrux Dds Pty Ltd | Method and composition for treatment or prophylaxis of amyloidosis disorders |
US20050123575A1 (en) | 2003-12-03 | 2005-06-09 | Eilon Asculai | Spreadable compositions for topical use, an improved process of making same and methods of using same |
ES2691498T3 (es) | 2004-03-03 | 2018-11-27 | Revance Therapeutics, Inc. | Aplicación tópica y liberación transdérmica de toxinas botulínicas |
EP1634583A1 (en) | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Testosterone gels comprising propylene glycol as penetration enhancer |
NZ563946A (en) * | 2005-06-03 | 2012-02-24 | Acrux Dds Pty Ltd | Testosterone containing non-occlusive transdermal drug delivery composition for application to the arm pit / axilla |
-
2003
- 2003-06-24 KR KR1020047021362A patent/KR20050045946A/ko not_active Application Discontinuation
- 2003-06-24 NZ NZ537360A patent/NZ537360A/en not_active IP Right Cessation
- 2003-06-24 EP EP03729716.5A patent/EP1534235B1/en not_active Revoked
- 2003-06-24 AU AU2003240301A patent/AU2003240301B2/en not_active Ceased
- 2003-06-24 CA CA2489865A patent/CA2489865C/en not_active Expired - Fee Related
- 2003-06-24 EA EA200500084A patent/EA009024B1/ru not_active IP Right Cessation
- 2003-06-24 KR KR1020107009520A patent/KR20100055542A/ko active Search and Examination
- 2003-06-24 WO PCT/AU2003/000787 patent/WO2004000263A1/en active Application Filing
- 2003-06-24 JP JP2004514440A patent/JP5160018B2/ja not_active Expired - Fee Related
- 2003-06-24 BR BRPI0312007-4A patent/BRPI0312007B1/pt not_active IP Right Cessation
- 2003-06-24 ES ES03729716.5T patent/ES2589077T3/es not_active Expired - Lifetime
- 2003-06-24 EP EP10010704A patent/EP2266533A3/en not_active Withdrawn
-
2004
- 2004-12-07 US US11/004,926 patent/US8357393B2/en not_active Expired - Fee Related
-
2005
- 2005-10-14 HK HK05109101.2A patent/HK1077192A1/zh not_active IP Right Cessation
-
2009
- 2009-12-18 US US12/642,301 patent/US20100166674A1/en not_active Abandoned
-
2012
- 2012-04-12 JP JP2012090664A patent/JP5568108B2/ja not_active Expired - Fee Related
- 2012-12-11 US US13/710,761 patent/US8784878B2/en not_active Expired - Fee Related
-
2014
- 2014-06-16 US US14/305,529 patent/US20150094290A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2266533A3 (en) | 2011-12-14 |
ES2589077T3 (es) | 2016-11-10 |
US8357393B2 (en) | 2013-01-22 |
JP2006501172A (ja) | 2006-01-12 |
WO2004000263A1 (en) | 2003-12-31 |
CA2489865C (en) | 2012-05-08 |
EA200500084A1 (ru) | 2005-06-30 |
US20100166674A1 (en) | 2010-07-01 |
AU2003240301B2 (en) | 2008-02-14 |
CA2489865A1 (en) | 2003-12-31 |
US20150094290A1 (en) | 2015-04-02 |
JP5160018B2 (ja) | 2013-03-13 |
HK1077192A1 (zh) | 2006-02-10 |
JP5568108B2 (ja) | 2014-08-06 |
EP2266533A2 (en) | 2010-12-29 |
EP1534235A4 (en) | 2008-06-18 |
US8784878B2 (en) | 2014-07-22 |
KR20100055542A (ko) | 2010-05-26 |
JP2012162557A (ja) | 2012-08-30 |
EP1534235A1 (en) | 2005-06-01 |
US20130316996A1 (en) | 2013-11-28 |
EP1534235B1 (en) | 2016-07-27 |
BRPI0312007B1 (pt) | 2015-04-14 |
AU2003240301A1 (en) | 2004-01-06 |
KR20050045946A (ko) | 2005-05-17 |
EA009024B1 (ru) | 2007-10-26 |
NZ537360A (en) | 2006-09-29 |
US20050175680A1 (en) | 2005-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0312007A (pt) | Controle de taxa de administração transcutânea usando composições farmacêuticas amorfas | |
Paudel et al. | Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers | |
ES2880624T3 (es) | Preparaciones tópicas de vasoconstrictores y métodos para proteger células durante quimioterapia y radioterapia contra el cáncer | |
DK1311249T3 (da) | Sæt af transdermale terapeutiske systemer | |
HK1088547A1 (en) | Once daily dosage forms of trospium trospium | |
BR0016012A (pt) | Implante farmacêutico contendo componentes de liberação imediata e de liberação prolongada, além de processo de administração | |
ATE544447T1 (de) | Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung | |
CY1109861T1 (el) | Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης | |
DK1256343T3 (da) | Flibanserin til behandlingen af extrapyramidale bevægelseslidelser | |
CO5130022A1 (es) | Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial | |
BR0308137A (pt) | Formulações de droga de liberação constante contendo um peptìdeo veìculo | |
DE60211139D1 (de) | Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp | |
WO2002034267A8 (de) | Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen | |
BR0309057A (pt) | Formulações lìquidas com baixa dosagem em entecavir e uso | |
KR20110031076A (ko) | 구강용 연고 | |
AR046146A1 (es) | Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso | |
BR0312004A (pt) | Composições de aerossol transdérmicas | |
EA200400348A1 (ru) | Цисплатиновые составы пониженной токсичности и способы их применения | |
BR0316770A (pt) | Formulação farmacêutica, método de produção da mesma e método de tratamento médico | |
JP2004203824A (ja) | 鼻腔用組成物及びその使用方法 | |
BR0208475A (pt) | Solução para administração intravenosa, e, método para a produção de uma solução de amiodarona adequada para administração intravenosa | |
BR0312003A (pt) | Composições farmacêuticas metaestáveis para distribuição transdérmica e seus usos | |
JP2017226618A (ja) | リュープロレリンの経皮吸収型製剤 | |
AR024199A1 (es) | Uso de la buprenorfina en la preparacion de un disposotivo de suministro transdermico | |
JP2014122167A (ja) | 眼科用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: A61K 9/00, A61K 9/12, A61K 9/70, A61P 25/22 Ipc: A61K 9/00 (2011.01), A61K 9/06 (2011.01), A61K 9/1 |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/04/2015, OBSERVADAS AS CONDICOES LEGAIS. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |